Cerus Corporation (CERS)

Currency in USD
2.195
+0.045(+2.09%)
Real-time Data·
Advertisement
CERS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1552.290
52 wk Range
1.1503.470
Key Statistics
Prev. Close
2.15
Open
2.23
Day's Range
2.155-2.29
52 wk Range
1.15-3.47
Volume
3.04M
Average Volume (3m)
2.64M
1-Year Change
72.8346%
Book Value / Share
0.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.500
Upside
+105.01%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Cerus Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.500
(+105.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy4.00+81.82%-Upgrade01/05/2026
TD Cowen
Buy5.00+127.27%-Maintain12/01/2026
BTIG
Hold---Maintain17/11/2025
TD Cowen
Buy5.00+127.27%-Maintain12/09/2025
BTIG
Hold---Maintain22/08/2025

Cerus Corporation Earnings Call Summary for Q2/2026

  • Cerus beat Q2 estimates with adjusted EPS loss of $0.01 vs. $0.03 expected and revenue of $63.3M, but shares fell 15.2% after hours on margin concerns.
  • Product revenue rose 10% YoY to $57.4M; company raised FY 2026 guidance to $229M-$231M, projecting 11-12% growth driven by IFC and core platelet business.
  • Gross margin declined to 51.4% from 55.2% YoY due to euro strength and inflation; operating cash flow negative $2.7M despite ninth straight positive EBITDA quarter.
  • Management expects GAAP profitability ahead with INT200 device U.S. approval targeted for H1 2027 and Phase III RedeS trial results due Q4 2026.
  • IFC franchise grew 40% excluding prior-year items to $6.7M; U.S. platelet penetration at two-thirds while IFC holds only 10% market share, signaling growth runway.
Last Updated: 30/07/2026, 22:18
Read Full Transcript

Earnings

Latest Release
30/07/2026
EPS / Forecast
-0.01 / -0.03
Revenue / Forecast
63.3M / 62.9M
EPS Revisions
Last 90 days

Cerus (CERS) Income Statement & Profits

Compare CERS to Peers and Sector

Metrics to compare
CERS
Peers
Sector
Relationship
P/E Ratio
−65.4x12.8x−0.4x
PEG Ratio
−0.98−0.010.00
Price/Book
6.3x2.2x2.6x
Price / LTM Sales
2.0x2.5x3.0x
Upside (Analyst Target)
109.3%43.3%56.0%
Fair Value Upside
Unlock17.3%9.1%Unlock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
66.18M33.03%142.28M
Other Institutional Investors
88.44M44.14%190.15M
Public Companies & Retail Investors
45.75M22.83%98.36M
Total
200.37M100.00%430.79M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.77%21,575,41946,387
ARK Investment Management LLC9.56%19,161,14841,196

People Also Watch

1.0700
ABTS
+4.90%
7.1900
AKTX
-8.52%
1.125
BSIN
-1.32%
20.27
TNDM
+3.92%

FAQ

What Is the Cerus (NASDAQ: CERS) Share Price Today?

The Cerus stock price today is 2.195 USD.

What Stock Exchange Does Cerus (CERS) Trade On?

Cerus is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Cerus?

The stock symbol (also called a 'ticker') for Cerus is "CERS."

What Is the Current Cerus Market Capitalisation?

As of today, Cerus (NASDAQ: CERS) market cap is 441.140M USD.

What Is Cerus's (CERS) Earnings Per Share (TTM)?

The Cerus EPS is currently -0.035 (Trailing Twelve Months).

When Is the Next Cerus Earnings Date?

Cerus's next earnings report will be released on 29/10/2026.

Is CERS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Cerus moving averages and other technical indicators, the daily buy/sell signal for CERS stock is Strong Sell.

How Many Times Has Cerus Stock Split?

Cerus has split 0 times. (See the CERS stock split history page for full effective split date and price information.)

How Many Employees Does Cerus Have?

Cerus has 268 employees, based on their latest Companies House report.

What is the current trading status of Cerus (NASDAQ: CERS)?

As of 03/08/2026, Cerus (CERS) is trading at a share price of 2.195 USD, with a previous close of 2.150 USD. The stock has fluctuated within a day range of 2.155 USD to 2.290 USD, while its 52-week range spans from 1.150 USD to 3.470 USD.

What Is Cerus (CERS) Price Target According to Analysts?

The average 12-month price target for Cerus is 4.500 USD, with a high estimate of 5 USD and a low estimate of 4 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +105.01% Upside potential.

What Is the CERS Premarket Price?

CERS's last pre-market stock price is 2.255 USD. The pre-market share volume is 30,260.000, and the stock has decreased by 0.105, or 4.880%.

What Is the CERS After Hours Price?

CERS's last after hours stock price is 2.200 USD, the stock has decreased by 0.050, or 2.330%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.